OncoMatch/Clinical Trials/Adagrasib
Adagrasib (MRTX849) Clinical Trials
Adagrasib (Krazati, MRTX849) is an irreversible, covalent KRAS G12C inhibitor with a long half-life (~23 hours) and CNS penetration, approved by the FDA in 2022 for previously treated KRAS G12C–mutant NSCLC based on the KRYSTAL-1 trial. Adagrasib combined with cetuximab received FDA accelerated approval for KRAS G12C–mutant colorectal cancer in March 2024 (KRYSTAL-10), making it the first approved combination regimen for this genomic subgroup. Active trials continue to investigate adagrasib with checkpoint inhibitors, chemotherapy, and novel targeted agents across NSCLC, pancreatic cancer, and tumor-agnostic settings, including confirmatory studies in colorectal cancer. Eligibility requires confirmed KRAS G12C mutation by an approved assay; prior therapy requirements vary by indication and trial line.
Check your eligibilityRecruiting Adagrasib trials
Ranked by phase and US site count. Filter by your biomarker profile →
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Mirati Therapeutics Inc.
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Ryan Gentzler, MD
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology, Inc.
How OncoMatch helps you find Adagrasib trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every Adagrasib trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.